Brandal SHB, Mo T, Fangberget A, Nilsen LB, Geier OM, Bjørndal H, Holmen MM, Engebråten O, Garred Ø, Hole KH, Seierstad T (2026)
MRI for Predicting Response and 10-Year Outcome of Neoadjuvant Chemotherapy with or Without Additional Bevacizumab Treatment in HER2-Negative Breast Cancer
Cancers (Basel), 18 (3)
DOI 10.3390/cancers18030393, PubMed 41681863

Trnkova L, Burikova M, Soltysova A, Ficek A, Plava J, Cumova A, Rojikova L, Jakic K, Sedlackova E, Tichy B, Bystry V, Busato F, Shen Y, Matuskova M, Kucerova L, Øy GF, Mælandsmo GM, Fleischer T, Tost J, Miklikova S, Cihova M, Buocikova V, Smolkova B (2026)
Molecular profiling of chemotherapy-resistant breast cancer reveals DNA methylation remodeling associated with the acquisition of paclitaxel resistance
Drug Resist Updat, 85, 101350
DOI 10.1016/j.drup.2026.101350, PubMed 41529624

Riaza Montes M, Suárez B, Solano-Iturri JD, Lecumberri D, Iturregui AM, Lawrie CH, Armesto M, Nunes-Xavier CE, Pulido R, López JI, Angulo JC, Larrinaga G (2025)
Fibroblast Activation Protein Alpha (FAP) Expression Is Associated with Disease Recurrence and Poor Response to Tyrosine Kinase Inhibitors in Advanced Clear Cell Renal Cell Carcinoma
Int J Mol Sci, 26 (22)
DOI 10.3390/ijms262211112, PubMed 41303595